Research ExplorerPublicationsDie Behandlung von Vorhofflimmern im Alltag

Die Behandlung von Vorhofflimmern im Alltag

Standard

Die Behandlung von Vorhofflimmern im Alltag. / Meinertz, T; Willems, S.

In: INTERNIST, Vol. 49, No. 12, 12.2008, p. 1437-1442.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Meinertz, T & Willems, S 2008, 'Die Behandlung von Vorhofflimmern im Alltag', INTERNIST, vol. 49, no. 12, pp. 1437-1442. https://doi.org/10.1007/s00108-008-2152-6

APA

Meinertz, T., & Willems, S. (2008). Die Behandlung von Vorhofflimmern im Alltag. INTERNIST, 49(12), 1437-1442. https://doi.org/10.1007/s00108-008-2152-6

Vancouver

Meinertz T, Willems S. Die Behandlung von Vorhofflimmern im Alltag. INTERNIST. 2008 Dec;49(12):1437-1442. https://doi.org/10.1007/s00108-008-2152-6

Bibtex

@article{824cbca0902141d4b3a1ab82a71d692d,
title = "Die Behandlung von Vorhofflimmern im Alltag",
abstract = "Atrial fibrillation is the most common arrhythmia in the adult. During recent years the therapeutic strategy has markedly changed. Some of these changes can be summarized as follows: Basis therapy includes betablockers and - in patients with structural heart disease - ACE-inhibitors and AT(1)-Blockers respectively. Class 1C-antiarrhythmic agents (flecainide or propafenon) should be restricted to patients with no or minimal left ventricular impairment. Amiodaron is the drug of choice in patients refractory to class 1C-agents and in those with already reduced left ventricular function. The {"}pill-in-the-pocket{"} regime can be used successfully in patients without structural heart disease and rare episodes of atrial fibrillation.Catheter ablation for paroxysmal and short lasting chronic atrial fibrillation was introduced into the clinical practice in 2006. The European and US-American guidelines recommend this technique for patients with no or minimal structural heart disease who are highly symptomatic and refractory or intolerant to antiarrhythmic agents. Decisions for curative catheter ablation in patients with long standing atrial fibrillation, heart failure or valvular heart disease should be individualized but are to date not generally recommended.",
keywords = "Acute Disease, Amiodarone/therapeutic use, Anti-Arrhythmia Agents/therapeutic use, Atrial Fibrillation/diagnosis, Catheter Ablation, Chronic Disease, Electric Countershock, Humans, Internal Medicine, Secondary Prevention",
author = "T Meinertz and S Willems",
year = "2008",
month = dec,
doi = "10.1007/s00108-008-2152-6",
language = "Deutsch",
volume = "49",
pages = "1437--1442",
journal = "INTERNIST",
issn = "0020-9554",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Die Behandlung von Vorhofflimmern im Alltag

AU - Meinertz, T

AU - Willems, S

PY - 2008/12

Y1 - 2008/12

N2 - Atrial fibrillation is the most common arrhythmia in the adult. During recent years the therapeutic strategy has markedly changed. Some of these changes can be summarized as follows: Basis therapy includes betablockers and - in patients with structural heart disease - ACE-inhibitors and AT(1)-Blockers respectively. Class 1C-antiarrhythmic agents (flecainide or propafenon) should be restricted to patients with no or minimal left ventricular impairment. Amiodaron is the drug of choice in patients refractory to class 1C-agents and in those with already reduced left ventricular function. The "pill-in-the-pocket" regime can be used successfully in patients without structural heart disease and rare episodes of atrial fibrillation.Catheter ablation for paroxysmal and short lasting chronic atrial fibrillation was introduced into the clinical practice in 2006. The European and US-American guidelines recommend this technique for patients with no or minimal structural heart disease who are highly symptomatic and refractory or intolerant to antiarrhythmic agents. Decisions for curative catheter ablation in patients with long standing atrial fibrillation, heart failure or valvular heart disease should be individualized but are to date not generally recommended.

AB - Atrial fibrillation is the most common arrhythmia in the adult. During recent years the therapeutic strategy has markedly changed. Some of these changes can be summarized as follows: Basis therapy includes betablockers and - in patients with structural heart disease - ACE-inhibitors and AT(1)-Blockers respectively. Class 1C-antiarrhythmic agents (flecainide or propafenon) should be restricted to patients with no or minimal left ventricular impairment. Amiodaron is the drug of choice in patients refractory to class 1C-agents and in those with already reduced left ventricular function. The "pill-in-the-pocket" regime can be used successfully in patients without structural heart disease and rare episodes of atrial fibrillation.Catheter ablation for paroxysmal and short lasting chronic atrial fibrillation was introduced into the clinical practice in 2006. The European and US-American guidelines recommend this technique for patients with no or minimal structural heart disease who are highly symptomatic and refractory or intolerant to antiarrhythmic agents. Decisions for curative catheter ablation in patients with long standing atrial fibrillation, heart failure or valvular heart disease should be individualized but are to date not generally recommended.

KW - Acute Disease

KW - Amiodarone/therapeutic use

KW - Anti-Arrhythmia Agents/therapeutic use

KW - Atrial Fibrillation/diagnosis

KW - Catheter Ablation

KW - Chronic Disease

KW - Electric Countershock

KW - Humans

KW - Internal Medicine

KW - Secondary Prevention

U2 - 10.1007/s00108-008-2152-6

DO - 10.1007/s00108-008-2152-6

M3 - SCORING: Review

C2 - 19020848

VL - 49

SP - 1437

EP - 1442

JO - INTERNIST

JF - INTERNIST

SN - 0020-9554

IS - 12

ER -